Improved Outcome with Gefitinib in Recurrent Middle Ear Squamous Cell Carcinoma XD04-XD05
Dr. Madhup Rastogi,
Professor and Head, Department of Radiation Oncology, Dr. Ram Manohar Lohia Institute of Medical Sciences,
Vibhuti Khand, Lucknow-226010, Uttar Pradesh, India.
Middle ear and external ear malignancies are rare. There is lack of consensus in managing such cases. Surgery followed by radiotherapy is the best option for advanced cancers, while radiotherapy alone in radical doses is sufficient for early disease. There is also dearth of literature in management of recurrence or metastasis. We present the case of a 25-year-old boy who had recurrence following surgery and radiotherapy for middle ear Squamous Cell Carcinoma (SCC). He was started on gefitinib and showed remarkable improvement in symptoms within two months of the treatment.